Muscle Wasting Diseases: Novel Targets and Treatments.

Annual Review of Pharmacology and Toxicology
Regula Furrer, Christoph Handschin

Abstract

Adequate skeletal muscle plasticity is an essential element for our well-being, and compromised muscle function can drastically affect quality of life, morbidity, and mortality. Surprisingly, however, skeletal muscle remains one of the most under-medicated organs. Interventions in muscle diseases are scarce, not only in neuromuscular dystrophies, but also in highly prevalent secondary wasting pathologies such as sarcopenia and cachexia. Even in other diseases that exhibit a well-established risk correlation of muscle dysfunction due to a sedentary lifestyle, such as type 2 diabetes or cardiovascular pathologies, current treatments are mostly targeted on non-muscle tissues. In recent years, a renewed focus on skeletal muscle has led to the discovery of various novel drug targets and the design of new pharmacological approaches. This review provides an overview of the current knowledge of the key mechanisms involved in muscle wasting conditions and novel pharmacological avenues that could ameliorate muscle diseases.

References

Nov 30, 2000·Proceedings of the National Academy of Sciences of the United States of America·B WangX Xiao
Mar 7, 2002·Lancet·Alan E H Emery
Aug 27, 2003·The Journal of Biological Chemistry·Daniel M FassRichard H Goodman
Oct 14, 2004·Cell·Dongsheng CaiSteven E Shoelson
Jan 15, 2005·The Journal of Clinical Investigation·Yao-Hua SongPatrick Delafontaine
Jul 5, 2006·Nature Medicine·Paul GregorevicJeffrey S Chamberlain
Feb 8, 2007·American Journal of Physiology. Endocrinology and Metabolism·Miriam GranadoAsunción López-Calderón
Feb 23, 2007·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Charu DograAshok Kumar
Apr 4, 2007·Genes & Development·Christoph HandschinBruce M Spiegelman
Apr 24, 2007·Nature·Ellen M WelchH Lee Sweeney
Dec 28, 2007·The New England Journal of Medicine·Judith C van DeutekomGert-Jan B van Ommen
Jul 25, 2008·Nature·Christoph Handschin, Bruce M Spiegelman
Sep 20, 2008·Journal of Applied Physiology·Brian T SteffenFrank W Booth
Feb 12, 2009·Muscle & Nerve·Louise R Rodino-KlapacJerry R Mendell
Apr 10, 2009·American Journal of Physiology. Cell Physiology·Anne Ulrike TrendelenburgDavid J Glass
Apr 10, 2009·American Journal of Physiology. Cell Physiology·Roberta SartoriMarco Sandri
Aug 12, 2009·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Aminah JatoiCharles L Loprinzi
Oct 6, 2009·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Giovanni MantovaniFilomena Panzone
Oct 9, 2009·Journal of Cell Science·Mathieu Laplante, David M Sabatini
Mar 24, 2010·The Journal of Cell Biology·Ashwani MittalAshok Kumar
Jul 28, 2010·Proceedings of the National Academy of Sciences of the United States of America·Céline ChambonDaniel Metzger
Oct 12, 2010·The New England Journal of Medicine·Jerry R MendellChristopher M Walker
Oct 13, 2010·Annual Review of Pharmacology and Toxicology·Markus A Rüegg, David J Glass
Apr 21, 2011·Molecular Therapy : the Journal of the American Society of Gene Therapy·HaiFang YinMatthew Ja Wood
May 13, 2011·Science Translational Medicine·Tyesha N BurksRonald D Cohn

❮ Previous
Next ❯

Citations

Jan 10, 2019·Annual Review of Pharmacology and Toxicology·Paul A InselUrs A Meyer
Feb 6, 2020·Journal of Cachexia, Sarcopenia and Muscle·Aolin YangDifei Wang
Feb 20, 2020·Current Opinion in Clinical Nutrition and Metabolic Care·Anthony J SannicandroKatarzyna Goljanek-Whysall
Jun 28, 2020·JPEN. Journal of Parenteral and Enteral Nutrition·Olgun DenizMeltem Halil
Apr 16, 2019·Frontiers in Physiology·Rosanna Piccirillo
Aug 15, 2019·Alcoholism, Clinical and Experimental Research·Kristin T CrowellCharles H Lang
Aug 1, 2020·Frontiers in Pharmacology·Yi LiPeifu Tang
Nov 5, 2019·Biochimica Et Biophysica Acta. Molecular Basis of Disease·Anton De SpiegeleerEvelien Wynendaele
Nov 30, 2020·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Lin YinGuanhua Du
Jan 9, 2021·Cell Death & Disease·Tamaki KurosawaAkiyoshi Uezumi
Dec 25, 2019·Biochimica Et Biophysica Acta. Molecular Basis of Disease·Anton De SpiegeleerEvelien Wynendaele
Jun 10, 2021·Communications Biology·James MooreErik C Böttger
Oct 15, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Sang Hee ParkJae Youl Cho
Jul 25, 2021·Scientific Reports·Wai W CheungRobert H Mak
Aug 8, 2021·International Journal of Molecular Sciences·Marco Antonio Lacerda-Abreu, José Roberto Meyer-Fernandes
Aug 25, 2021·Proceedings of the National Academy of Sciences of the United States of America·Lin LiuYumiko Oishi
Aug 14, 2021·Current Opinion in Otolaryngology & Head and Neck Surgery·Joy ChenMarianne Abouyared
Aug 31, 2021·Frontiers in Physiology·Aurel B LeuchtmannChristoph Handschin
Aug 20, 2021·Frontiers in Genetics·Olivier BoyerUNKNOWN Study Group

❮ Previous
Next ❯

Methods Mentioned

BETA
ubiquitination
nuclear translocation
glycosylation
antisense oligonucleotides

Clinical Trials Mentioned

NCT02138422
NCT03207724
NCT02072057
NCT00046904
NCT00802815
NCT00060502
NCT00040885
NCT01127386
NCT00379353
NCT01021072

Related Concepts

Related Feeds

Cardiac Cachexia

Cardiac cachexia is a syndrome associated with the progressive loss of muscle and fat mass. It most commonly affects patients with heart failure and can significantly decrease the quality of life and survival in these patients. Here is the latest research on cardiac cachexia.

Cachexia & Brown Fat

Cachexia is a condition associated with progressive weight loss due to severe illness. In cancer patients, it is proposed to occur as a result of tumor-induced energy wasting. Several proteins have been implicated in browning and depletion of white adipose tissue. Here is the latest research on cachexia and brown fat.